← Leaderboards
Hardy Kornfeld
Univ Of Massachusetts Med Sch Worcester
$32,043,759
Attributed
$36,646,552
Total exposure
13
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.9M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,646,552 · 13
By mechanism
R01$20,741,020 · 7
C06$7,857,615 · 1
G20$3,994,219 · 1
U01$2,902,833 · 1
R21$896,935 · 2
R34$253,930 · 1
Top collaborators
- Amit Singhal14 shared
- Robert S Wallis5 shared
Most similar at Univ Of Massachusetts Med Sch Worcester
Same institution · by research overlap
- Raymond M Welsh$22,465,901
- Amit Singhal$3,635,183
- Sumner H Burstein$1,791,353
Others in their field
Top investigators on “Mycobacterium Tuberculosis”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$267,251,837
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Kevin Urdahl · Seattle Children'S Hospital$86,597,961
- David Alland · Rutgers Biomedical And Health Sciences$70,943,567
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- William Robert Jacobs · Albert Einstein College Of Medicine$43,123,310
Research focus
Mycobacterium TuberculosisTuberculosisLungResponseInfectionImmunityPathway InteractionsImmuneHost DefenseMacrophageInflammationAerosolsCellsMediatingCytokineAntimicrobialPathogenSignal TransductionImpairmentLinkPulmonary TuberculosisDiabetes MellitusBasePredisposition
Grant awards (57)
Unleashing CD8+ T Cells for TB Defense$197,475
R21 · FY2025 · AI · contact PI
A Biosafety Level 3 Laboratory for Viral Pathogens$7,857,615
C06 · FY2024 · OD · contact PI
Trial of Metformin for TB/HIV Host-directed Therapy$624,591
U01 · FY2024 · AI · contact PI
Sirtuins and Host Metabolism in TB Pathogenesis and Treatment$608,967
R01 · FY2024 · HL · contact PI
Lung-Protective Mechanisms of Metformin in TB$604,331
R01 · FY2024 · HL · contact PI
Unleashing CD8+ T Cells for TB Defense$249,085
R21 · FY2024 · AI · contact PI
Lung-Protective Mechanisms of Metformin in TB$637,617
R01 · FY2023 · HL · contact PI
Sirtuins and Host Metabolism in TB Pathogenesis and Treatment$628,640
R01 · FY2023 · HL · contact PI
Trial of Metformin for TB/HIV Host-directed Therapy$350,645
U01 · FY2023 · AI · contact PI
BSL3 Enhancements for RNA Virus Pandemic Preparedness$3,994,219
G20 · FY2022 · AI · contact PI
Lung-Protective Mechanisms of Metformin in TB$647,877
R01 · FY2022 · HL · contact PI
Sirtuins and Host Metabolism in TB Pathogenesis and Treatment$636,398
R01 · FY2022 · HL · contact PI
Trial of Metformin for TB/HIV Host-directed Therapy$567,738
U01 · FY2022 · AI · contact PI
Sirtuins and Host Metabolism in TB Pathogenesis and Treatment$663,956
R01 · FY2021 · HL · contact PI
Lung-Protective Mechanisms of Metformin in TB$658,272
R01 · FY2021 · HL · contact PI
Trial of Metformin for TB/HIV Host-directed Therapy$787,888
U01 · FY2020 · AI · contact PI
Trial of Metformin for TB/HIV Host-directed Therapy$571,971
U01 · FY2019 · AI · contact PI
Determinants of Tuberculosis Severity$548,586
R01 · FY2019 · HL · contact PI
Impact of Diabetes and Hyperlipidemia on Host Defense$418,750
R01 · FY2019 · HL · contact PI
Determinants of Tuberculosis Severity$548,586
R01 · FY2018 · HL · contact PI
Impact of Diabetes and Hyperlipidemia on Host Defense$418,750
R01 · FY2018 · HL · contact PI
Determinants of Tuberculosis Severity$548,586
R01 · FY2017 · HL · contact PI
Impact of Diabetes and Hyperlipidemia on Host Defense$418,750
R01 · FY2017 · HL · contact PI
Determinants of Tuberculosis Severity$548,586
R01 · FY2016 · HL · contact PI
Impact of Diabetes and Hyperlipidemia on Host Defense$418,750
R01 · FY2016 · HL · contact PI
Planning for the Metformin for TB/HIV Host-directed Therapy (METHOD) Trial$253,930
R34 · FY2016 · AI · contact PI
Impact of Diabetes and Hyperlipidemia on Host Defense$403,025
R01 · FY2014 · HL · contact PI
Impact of Diabetes and Hyperlipidemia on Host Defense$391,510
R01 · FY2013 · HL · contact PI
Impact of Diabetes and Hyperlipidemia on Host Defense$411,250
R01 · FY2012 · HL · contact PI
Impact of Diabetes and Hyperlipidemia on Host Defense$411,250
R01 · FY2011 · HL · contact PI
Antimycobacterial Mechanisms of Apoptosis in the Lung$394,469
R01 · FY2010 · HL · contact PI
Impact of Diabetes and Hyperlipidemia on Host Defense$394,469
R01 · FY2010 · HL · contact PI
Antimycobacterial Mechanisms of Apoptosis in the Lung$394,469
R01 · FY2009 · HL · contact PI
Impact of Diabetes and Hyperlipidemia on Host Defense$394,469
R01 · FY2009 · HL · contact PI
Acquired susceptibility to pulmonary TB$246,000
R21 · FY2009 · AI · contact PI
Impact of Diabetes and Hyperlipidemia on Host Defense$394,469
R01 · FY2008 · HL · contact PI
Antimycobacterial Mechanisms of Apoptosis in the Lung$394,469
R01 · FY2008 · HL · contact PI
Acquired susceptibility to pulmonary TB$204,375
R21 · FY2008 · AI · contact PI
Antimycobacterial Mechanisms of Apoptosis in the Lung$394,469
R01 · FY2007 · HL · contact PI
Impact of Diabetes and Hyperlipidemia on Host Defense$394,469
R01 · FY2007 · HL · contact PI
Antimycobacterial Mechanisms of Apoptosis in the Lung$406,250
R01 · FY2006 · HL · contact PI
Impact of Diabetes and Hyperlipidemia on Host Defense$405,938
R01 · FY2006 · HL · contact PI
IL-16 in Pulmonary Cryptococcosis$388,159
R01 · FY2006 · HL · contact PI
ANTIMYCOBACTERIAL MECHANISMS OF APOPTOSIS IN THE LUNG$428,882
R01 · FY2005 · HL
IL-16 in Pulmonary Cryptococcosis$397,500
R01 · FY2005 · HL
ANTIMYCOBACTERIAL MECHANISMS OF APOPTOSIS IN THE LUNG$418,363
R01 · FY2004 · HL
IL-16 in Pulmonary Cryptococcosis$397,500
R01 · FY2004 · HL
NOVEL MECHANISM OF INNATE DEFENSE IN MURINE TB$534,970
R01 · FY2003 · HL
ANTIMYCOBACTERIAL MECHANISMS OF APOPTOSIS IN THE LUNG$408,153
R01 · FY2003 · HL
IL-16 in Pulmonary Cryptococcosis$397,500
R01 · FY2003 · HL
NOVEL MECHANISM OF INNATE DEFENSE IN MURINE TB$529,220
R01 · FY2002 · HL
ANTIMYCOBACTERIAL MECHANISMS OF APOPTOSIS IN THE LUNG$403,102
R01 · FY2002 · HL
IL-16 in Pulmonary Cryptococcosis$387,470
R01 · FY2002 · HL
NOVEL MECHANISM OF INNATE DEFENSE IN MURINE TB$529,220
R01 · FY2001 · HL
ANTIMYCOBACTERIAL MECHANISMS OF APOPTOSIS IN THE LUNG$409,136
R01 · FY2001 · HL
NOVEL MECHANISM OF INNATE DEFENSE IN MURINE TB$530,850
R01 · FY2000 · HL
NOVEL MECHANISM OF INNATE DEFENSE IN TUBERCULOSIS$40,618
R01 · FY2000 · HL